LAMZEDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LAMZEDE (LAMZEDE).
Recombinant human iduronate-2-sulfatase (idursulfase) replaces deficient or absent iduronate-2-sulfatase enzyme, which hydrolyzes the 2-sulfate groups from the heparan sulfate and dermatan sulfate GAGs, preventing their accumulation in lysosomes.
| Metabolism | Idursulfase is a protein; it is expected to be degraded via general protein catabolism into small peptides and amino acids. |
| Excretion | Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal elimination accounts for >90% of the administered dose. |
| Half-life | Terminal elimination half-life is approximately 100-120 hours. This long half-life supports weekly dosing and maintains therapeutic concentrations throughout the dosing interval. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 100-150 mL/kg (0.1-0.15 L/kg), indicating limited distribution primarily to the extracellular space. |
| Bioavailability | Intramuscular injection: Bioavailability is not established; administered as a solution for IM injection. Subcutaneous and intravenous routes are not approved. Oral bioavailability is negligible due to protein nature. |
| Onset of Action | Intramuscular injection: Clinical improvement in walking ability and motor function observed within 3-6 months of initiating treatment. |
| Duration of Action | Duration of effect is approximately 1 week, consistent with the dosing interval. Sustained efficacy requires continued weekly administration. |
Intravenous infusion: 1 mg/kg once weekly.
| Dosage form | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Intravenous infusion: 1 mg/kg once weekly; same as adult dosing. |
| Geriatric use | No specific dose adjustment; use with caution due to age-related comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LAMZEDE (LAMZEDE).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need. |
| Teratogenic Risk | Lamzede (velmanase alfa) has not been studied in pregnant women. Animal studies show no evidence of fetal harm at doses up to 5 times the human exposure. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Anaphylaxis and severe hypersensitivity reactions, including potentially life-threatening anaphylaxis, have occurred in patients treated with LAMZEDE. Patients should be monitored closely during infusion and for an appropriate period after infusion. Appropriate medical support should be readily available.
| Serious Effects |
["None known"]
| Precautions | ["Anaphylaxis and hypersensitivity reactions","Risk of acute respiratory compromise and/or chronic respiratory insufficiency","Risk of cardiac complications (including arrhythmia, heart failure)","Risk of infusion reactions (including fever, chills, rash, urticaria)","Need for premedication and monitoring during infusions","Potential for immune complex formation and delayed hypersensitivity"] |
Loading safety data…
| No specific monitoring required beyond standard obstetrical care. Monitor for infusion-related reactions if administered during pregnancy. |
| Fertility Effects | No human data on fertility effects. Animal studies showed no impairment of male or female fertility at doses up to 5 times the human exposure. |